Pladevall-Morera et al. have studied combination treatments of TMZ and various RTKs, including a PDGFR inhibitor, in high-grade gliomas exhibiting ATRX and PDGFR mutations, which resulted in a high sensitivity of HGG cells to these treatment combinations [29]. The gene discussed is PDGFRB; the disease is central nervous system cancer.